Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Study identifier:MB102-037

ClinicalTrials.gov identifier:NCT00842556

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Dapagliflozin, Glimepiride, Sitagliptin

Sex

All

Actual Enrollment

18

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Mar 2009
Primary Completion Date: 01 May 2009
Study Completion Date: 01 May 2009

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria